Treatment of hairy cell leukaemia with recombinant alpha interferon. 1989

K R Romeril, and J M Carter, and G J Green, and M E Beard, and D C Heaton, and C H Newhook, and S S Gibbons, and J Reddy
Wellington Hospital.

Eleven patients with progressive hairy cell leukaemia (three nonsplenectomised) were treated with recombinant alpha-2 interferon (Intron-A or Roferon-A) subcutaneously three times per week at a dosage of 3 x 10(6) units. Ten patients completed at least ten weeks of therapy and could be evaluated; one patient died of haemorrhage from severe thrombocytopenia after only three weeks treatment. Nine of the ten patients responded and all of these are regarded as good partial remissions (normalisation of all blood parameters but still discernible hairy cells in the marrow). Responding patients have all been followed for a median of two years and in one case 3 1/2 years since commencement of therapy. The patients are all transfusion independent and free of infection. We conclude that alpha-2 interferon therapy for progressive hairy cell leukaemia is effective therapy in both splenectomised and nonsplenectomised patients.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007943 Leukemia, Hairy Cell A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow. Hairy Cell Leukemia,Leukemic Reticuloendotheliosis,Reticuloendotheliosis, Leukemic,Hairy Cell Leukemias,Leukemias, Hairy Cell,Leukemic Reticuloendothelioses,Reticuloendothelioses, Leukemic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

K R Romeril, and J M Carter, and G J Green, and M E Beard, and D C Heaton, and C H Newhook, and S S Gibbons, and J Reddy
November 1987, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
K R Romeril, and J M Carter, and G J Green, and M E Beard, and D C Heaton, and C H Newhook, and S S Gibbons, and J Reddy
May 1984, Lancet (London, England),
K R Romeril, and J M Carter, and G J Green, and M E Beard, and D C Heaton, and C H Newhook, and S S Gibbons, and J Reddy
February 1988, European journal of cancer & clinical oncology,
K R Romeril, and J M Carter, and G J Green, and M E Beard, and D C Heaton, and C H Newhook, and S S Gibbons, and J Reddy
July 1985, Scandinavian journal of haematology,
K R Romeril, and J M Carter, and G J Green, and M E Beard, and D C Heaton, and C H Newhook, and S S Gibbons, and J Reddy
August 1986, Blood,
K R Romeril, and J M Carter, and G J Green, and M E Beard, and D C Heaton, and C H Newhook, and S S Gibbons, and J Reddy
November 1988, European journal of haematology,
K R Romeril, and J M Carter, and G J Green, and M E Beard, and D C Heaton, and C H Newhook, and S S Gibbons, and J Reddy
February 1986, The New Zealand medical journal,
K R Romeril, and J M Carter, and G J Green, and M E Beard, and D C Heaton, and C H Newhook, and S S Gibbons, and J Reddy
March 1985, Blood,
K R Romeril, and J M Carter, and G J Green, and M E Beard, and D C Heaton, and C H Newhook, and S S Gibbons, and J Reddy
August 1986, European journal of cancer & clinical oncology,
K R Romeril, and J M Carter, and G J Green, and M E Beard, and D C Heaton, and C H Newhook, and S S Gibbons, and J Reddy
April 1992, British journal of haematology,
Copied contents to your clipboard!